Curis
CRIS

$6.12

1.66%

Market Cap: 36.1M

About: Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Employees: 49

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 4 analysts

0

News positive %

of 4 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

67% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 6

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

4.16% less ownership

Funds ownership: 39.62% [Q4 2023] → 35.46% (-4.16%) [Q1 2024]

11% less funds holding

Funds holding: 38 [Q4 2023] → 34 (-4) [Q1 2024]

24% less capital invested

Capital invested by funds: $29.8M [Q4 2023] → $22.7M (-$7.05M) [Q1 2024]

57% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 7

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$26

325%

upside

Avg. target

$26

325%

upside

High target

$26

325%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

Truist Securities Robyn Karnauskas	325%upside $26	Buy Maintained	15 May 2024
HC Wainwright & Co. Edward White	325%upside $26	Buy Reiterated	15 May 2024
HC Wainwright & Co. Edward White	325%upside $26	Buy Reiterated	8 May 2024
HC Wainwright & Co. Edward White	325%upside $26	Buy Maintained	9 Feb 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about CRIS published over the past 30 days

Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024

LEXINGTON, Mass. , July 25, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its second quarter 2024 financial and operating results on Thursday, August 1, 2024, at 8:00 a.m.

Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024

Curis to Present at Upcoming Healthcare Conference in July

LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the Jones Healthcare Seaside Summit 2024 on July 15, 2024 at 8:00 a.m.

Curis to Present at Upcoming Healthcare Conference in July

Zacks Investment Research

What Makes Curis (CRIS) a New Buy Stock

Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Curis (CRIS) a New Buy Stock

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass. , July 8, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that on July 1, 2024, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 25,000 shares of Curis common stock to a new employee, with a grant date of July 1, 2024 (the "Q3 2024 Inducement Grant").

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis Announces Additional Data from TakeAim Leukemia Study

Data update expands AML dataset from 5 to 30 patients LEXINGTON, Mass. , May 14, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced updated data from the ongoing TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) AML to be presented at the ASCO and EHA conferences.

Curis Announces Additional Data from TakeAim Leukemia Study

Curis to Present Updated Data from the TakeAim Leukemia Study

LEXINGTON, Mass. , May 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will present updated data from the TakeAim Leukemia study Tuesday, May 14, 2024, at 4:00 p.m.

Curis to Present Updated Data from the TakeAim Leukemia Study

Curis, Inc. (CRIS) Q1 2024 Earnings Call Transcript

Curis, Inc. (NASDAQ:CRIS ) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Diantha Duvall - CFO Jim Dentzer - President & CEO Robert Martell - Chief Scientific Officer Conference Call Participants Soumit Roy - JonesTrading Li Watsek - Cantor Fitzgerald Yale Jen - Laidlaw & Company Billal Jahangiri - Truist Securities Sean McCutcheon - Raymond James Operator Good morning, ladies and gentlemen, and welcome to the Curis First Quarter 2024 Business Update. At this time all lines are in listen-only mode.

Curis, Inc. (CRIS) Q1 2024 Earnings Call Transcript

Curis Provides First Quarter 2024 Business Update

Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.

Curis Provides First Quarter 2024 Business Update

Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024

LEXINGTON, Mass. , April 30, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will release its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:00 a.m.

Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024

Zacks Investment Research

Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?

Curis (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?

See News Rankings